Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
24 hedge funds and large institutions have $833K invested in Bellerophon Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
26% more funds holding
Funds holding: 19 → 24 (+5)
1.66% less ownership
Funds ownership: 11.35% → 9.69% (-1.7%)
30% less capital invested
Capital invested by funds: $1.18M → $833K (-$349K)
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$28.7K |
| 2 |
Millennium Management
New York
|
+$23.5K |
| 3 |
E
Ergoteles
New York
|
+$15.2K |
| 4 |
Jane Street
New York
|
+$14.1K |
| 5 |
NAM
NTV Asset Management
Charleston,
West Virginia
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$204K |
| 2 |
Renaissance Technologies
New York
|
-$25K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$9.21K |
| 5 |
TI
Telemetry Investments
New York
|
-$3.58K |
BLPH Hedge Fund Activity: Q4 2022 in Review
24 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2022, worth a combined $833K — down 30% from $1.18M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BLPH positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 8 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $28.7K. The largest seller was Vanguard Group, cutting an estimated $204K.
- 24 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2022, up from 19 in Q3 2022.
- Funds reported $833K of Bellerophon Therapeutics, Inc. stock for Q4 2022, down 30% quarter-over-quarter.
- 6 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2022 and 1 closed out, a net change of +5 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q4 2022 was HRT Financial, an estimated $28.7K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $204K sold.
Based on aggregated 13F filings for Q4 2022.